A Phase 1 Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects with Advanced Solid Tumors

Protocol: 
AAAR5080
Phase: 
I

A Phase 1 Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects with Advanced Solid Tumors

Are you Eligible? (Inclusion Criteria)

1. Have tumor(s) that cannot be removed (unresectable) or has spread
(metastasized) to a different part of the body.

2. Participants must be in good physical shape. This means that participants
must be able to walk, care for themselves, and do light physical activities
such as light housework or office work.

3. This study is for participants age 18 or older

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States